指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

肠易激综合征、功能性便秘及艰难梭菌感染患者益生菌使用的临床指导与实践建议:考虑性别差异

Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, and Clostridioides difficile Infection Considering Sex-based Differences.
指南 / 共识 · J Neurogastroenterol Motil · 2026-03-10
一句话结论益生菌可能作为肠易激综合征和功能性便秘的辅助治疗,但疗效具有菌株特异性且异质性大;当前指南通常不推荐常规用于预防艰难梭菌感染。

该专家综述基于随机对照试验和荟萃分析证据,为肠易激综合征、功能性便秘和艰难梭菌感染患者使用益生菌提供实践建议,并考虑可能的性别相关差异。证据显示益生菌可适度改善肠易激综合征的总体症状、腹痛和腹胀,并提高功能性便秘患者的排便频率和大便稠度,但效应具有菌株特异性且异质性大。临床试验未证实肠易激综合征中存在显著性别差异,而应激诱导的动物模型显示特定菌株的反应存在性别依赖。对于艰难梭菌感染,大型试验中益生菌预防原发或复发感染的疗效不一致,当前指南通常不推荐常规使用。益生菌对健康个体通常安全,但免疫功能受损或危重患者需谨慎。

要点

  • 益生菌可适度改善肠易激综合征的总体症状、腹痛和腹胀,但效应具有菌株特异性且异质性大。
  • 益生菌可提高功能性便秘患者的排便频率和大便稠度。
  • 肠易激综合征临床试验未证实显著性别相关差异,但应激诱导动物模型显示特定菌株反应存在性别依赖。
  • 艰难梭菌感染中益生菌预防原发或复发感染的疗效在大型试验中不一致,当前指南通常不推荐常规使用。
  • 益生菌对健康个体通常安全,但免疫功能受损或危重患者需谨慎;临床选择应基于菌株特异性证据、足够活菌剂量和患者特征或性别。

适用人群与场景

  • 肠易激综合征、功能性便秘和艰难梭菌感染患者,考虑可能的性别相关差异。
  • 益生菌对健康个体通常安全,但免疫功能受损或危重患者需谨慎。

处置流程与药物剂量

  • 临床医生应根据菌株特异性临床证据、足够的活菌剂量、患者特征或患者性别选择益生菌产品。
  • 对于艰难梭菌感染,当前指南通常不推荐常规使用益生菌预防原发或复发感染。

红旗征与不能漏的情况

  • 免疫功能受损或危重患者使用益生菌需谨慎。

研究设计与关键结果

  • 随机对照试验和荟萃分析证据表明,益生菌可适度改善肠易激综合征的总体症状、腹痛和腹胀,并提高功能性便秘患者的排便频率和大便稠度;这些效应具有菌株特异性且异质性大。
  • 肠易激综合征临床试验未证实显著的性别相关差异;应激诱导的肠易激综合征动物模型显示特定益生菌菌株的反应存在性别依赖,支持这种差异的生物学合理性。
  • 对于艰难梭菌感染,大型试验中益生菌预防原发或复发感染的疗效不一致,当前指南通常不推荐常规使用;免疫学的性别和年龄差异支持艰难梭菌感染的临床差异。
  • 益生菌对健康个体通常安全,但免疫功能受损或危重患者需谨慎。

证据类型、等级与局限

  • 证据类型:专家综述,基于随机对照试验和荟萃分析证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 临床医生应根据菌株特异性临床证据、足够的活菌剂量、患者特征或患者性别选择益生菌产品。
  • 益生菌可能作为肠易激综合征和功能性便秘的辅助治疗,但反应变异受微生物、宿主和潜在性别相关因素影响。
  • 对于艰难梭菌感染,当前指南通常不推荐常规使用益生菌预防原发或复发感染。
  • 免疫功能受损或危重患者使用益生菌需谨慎。
  • 需要进一步研究以建立优化的个性化益生菌策略。

指南或共识出处

  • J Neurogastroenterol Motil

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Probiotics have gained increasing clinical attention as adjunctive treatment for lower gastrointestinal disorders. However, evidence supporting their therapeutic efficacy remains limited, particularly with regard to sex-related differences. This expert review provides evidence-based insights and practical recommendations for the use of probiotics in patients with irritable bowel syndrome (IBS), functional constipation (FC), and Clostridioides difficile infection (CDI), considering possible sex-related differences. Evidence from randomized controlled trials and meta-analyses indicates that probiotics can modestly improve global symptoms, abdominal pain, and bloating in IBS and enhance bowel movement frequency and stool consistency in FC. However, these effects are strain-specific and heterogeneous. Although clinical studies on probiotics in IBS have not confirmed significant sex-related differences, experimental animal studies using stress-induced IBS models have demonstrated sex-dependent responses to specific probiotic strains, supporting the biological plausibility of such differences. For CDI, the efficacy of probiotics in preventing primary or recurrent infections remains inconsistent across large trials, and current guidelines usually do not recommend their routine use. However, sex and age difference of immunology supports the clinical differences of CDI. Probiotics are generally considered safe for healthy individuals, although caution is advised in patients who are immunocompromised or critically ill. Clinicians should select probiotic products based on strain-specific clinical evidence, adequate viable doses, patient's characteristics, or patient's sex. In conclusion, probiotics might play a role as adjunctive therapy for IBS and FC, with variability in responses influenced by microbial, host, and potential sex-related factors. Further research is needed to establish optimized personalized probiotic strategies.

来源:J Neurogastroenterol Motil,查看原文。版权归原作者所有。

参考来源

  1. Kim YS, Park SY, Kang SJ, et al. Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, and Clostridioides difficile Infection Considering Sex-based Differences. J Neurogastroenterol Motil. 2026. PMID: 41807013. doi:10.5056/jnm25221

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。